8-K - Brainstorm Cell Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

BrainStorm Cell Therapeutics Inc. announced full year 2025 financial results with reduced net loss and R&D expenses, $2.0 million post-year-end financing, and progress toward Phase 3b NurOwn trial for ALS.

Key Takeaways

1Net loss for 2025 was $10.3 million ($1.11 per share), improved from $11.6 million ($2.31 per share) in 2024.

2R&D expenses decreased to $4.2 million in 2025 from $4.7 million in 2024.

3G&A expenses fell to $5.8 million in 2025 from $7.0 million in 2024.

4Cash and equivalents were $0.3 million as of December 31, 2025; $2.0 million raised via private placements in February 2026.

5Phase 3b ENDURANCE study of NurOwn cleared by FDA, to enroll ~200 ALS patients with ALSFRS-R endpoint.

650% of EAP patients (5/10) alive at ~84 months survival, all tracheostomy-free as of July 2025.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or

Financial Results

9.01

Financial Statements and Exhibits.** (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release issued by Brainstorm Cell Therapeutics

Exhibits Only

Source Document

Results of Operations

Full Year

Metric	Value	Basis	Prior Period
Research and development expenditures, net	$4.20	GAAP	$4.70
General and administrative expenses	$5.80	GAAP	$7.00
Net loss	$10.30	GAAP	$11.60
Net loss per share	$1.11	GAAP	$2.31

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1